Clinical trials: Hemostatic Disorders
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NYSCT MM (NCT03506802)
- Testing
- 18F-FHBG, Aldesleukin, Cellular Therapy
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Multiple Myeloma
Expanded Access Treatment Protocol CA204-143
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S.
- Trial name
- NCT02368301
- Testing
- Elotuzumab in combination with Lenalidomide and Dexamethasone
- Sponsor
- Bristol-Myers Squibb
714leukemia, Lymphoma
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00671112
- Testing
- Bortezomib, Everolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brian Hill, MD, PhD
Bleeding Disorders, Iron
Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders
This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin <50ng/dL).
- Conditions
- Bleeding Disorders, Iron, Platelet, Bleeding
- Trial name
- IRON-BD (NCT07083583)
- Testing
- IV Iron (standard of care)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Nicoletta C Machin
Lymphoma, Waldenström Macroglobulinemia (WM)
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma
- Conditions
- Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL
- Trial name
- NCT07249905
- Testing
- MDX2003
- Where
- 6 sites in Australia, Israel
- Volunteers
- 180 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Recurrent Plasma Cell Myeloma
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
This phase II trial studies whether daratumumab and hyaluronidase-fihj and pomalidomide work in treating patients with multiple myeloma that has come back (relapsed) after stem cell transplant.
- Trial name
- NCT03622775
- Testing
- Daratumumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
This study aims to investigate the prognostic value of circulating plasma cells (CPCs) in patients with multiple myeloma and explore whether CPCs detection might be used in place of bone marrow aspiration for disease monitoring.
- Trial name
- NCT06228794
- Testing
- Peripheral blood test
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a…
- Trial name
- NCT04786028
- Testing
- Isatuximab
- Where
- 7 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Canadian Myeloma Research Group
Relapsed/Refractory Multiple Myeloma
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
An open label, single-arm clinical study evaluating the safety and efficacy of ICI201 infusion in relapsed/refractory multiple myeloma
- Trial name
- NCT05980507
- Testing
- ICI201
- Where
- China
- Sponsor
- The First Affiliated Hospital of Soochow University
Myocardial Ischemia, Blood Coagulation Disorders
"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
Aims and Hypotheses: This randomised placebo controlled study will test the hypothesis that Recombinant Activated Factor VII (rVIIa) will improve haemostasis after an inadequate response to conventional therapy in complex cardiac…
- Conditions
- Myocardial Ischemia, Blood Coagulation Disorders, Coronary Artery Disease, Heart Valve Diseases
- Trial name
- NCT00214656
- Testing
- Recombinant Activated Factor VII
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Austin Health
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Liver Cirrhosis, Coagulopathy
Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction
The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood products in preventing bleeding after teeth extraction…
- Trial name
- NCT00816127
- Testing
- Desmopressin, blood transfusion
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Myeloma
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can help to control the disease.
- Trial name
- NCT06105554
- Testing
- Belumosudil mesylate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Cataract, Retina Detachment
Different Hemostasis According to the Anesthetic Agents
We investigated the hemostatic differences according to the main anesthetic agents by analyzing rotational thromboelastometry (ROTEM) under the hypothesis that propofol-based anesthesia would impair postoperative coagulability…
- Conditions
- Cataract, Retina Detachment, Pterygium, Keratitis
- Trial name
- NCT02151305
- Testing
- Propofol, remifentanil, Sevoflurane
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Seoul National University Bundang Hospital
Kidney Cancer, Renal Cell Carcinoma
A Novel Haemostatic Agent for Robotic Partial Nephrectomy
Kidney cancer is one of only a few cancers with an increasing incidence over the past two decades. Renal cell carcinoma (RCC) accounts for over 85% of all kidney tumours, which makes up 2-3% of all adult malignancies.
- Trial name
- PuraBond (NCT07284953)
- Testing
- PuraBond
- Where
- United Kingdom
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Multiple Myeloma
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.
- Trial name
- BelaRd (NCT04808037)
- Testing
- Belantamab mafodotin
- Where
- Greece
- Volunteers
- 66 people
- Sponsor
- Hellenic Society of Hematology
Follicular Lymphoma, Mantle Cell Lymphoma
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
This is a non-randomized clinical trial to evaluate the safety and efficacy of CD22CART administered after lymphodepleting chemotherapy in adults with relapsed / refractory B Cell Lymphomas.
- Conditions
- Follicular Lymphoma, Mantle Cell Lymphoma, Hairy Cell Leukemia, Lymphoplasmacytic Lymphoma
- Trial name
- NCT06340737
- Testing
- CD22CART Infusion
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Stanford University
Multiple Myeloma, Caregiver Subjective Burden
The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study
The purpose of this observational study is to estimate the burden of multiple myeloma on patients and caregivers in terms of QoL.
- Conditions
- Multiple Myeloma, Caregiver Subjective Burden, Quality of Life (QOL)
- Trial name
- NCT06610045
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- PeriPharm
Multiple Myeloma
MInimal Residual Disease Adapted Strategy
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates.
- Trial name
- MIDAS (NCT04934475)
- Testing
- Isatuximab, ASCT
- Where
- 73 sites in Belgium, France and 1 more
- Volunteers
- 791 people
- Sponsor
- Intergroupe Francophone du Myelome
Multiple Myeloma
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
- Trial name
- NCT06997081
- Testing
- Lenalidomide, Dexamethasone, Elranatamab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Miami
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.